nach oben

Erschienen in:

16.11.2020 | Hodentumoren | Zertifizierte Fortbildung

Keimzelltumoren

Therapie von Hodentumoren

verfasst von: Priv.-Doz. Dr. med. Marcus Hentrich

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Auszug

Auch wenn Hodentumoren gemessen an allen Krebserkrankungen eine eher seltenere Entität repräsentieren, sind sie der häufigste Tumor bei Männern im jüngeren Lebensalter. Lesen Sie in der nachfolgenden Übersicht über den aktuellen Stand in der Diagnostik, Klassifikation und Behandlung von Hodentumoren. …

Robert Koch-Institut. Zentrum für Krebsregisterdaten. 2019. https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2019/kid_2019_c62_hoden.pdf abgerufen am 17. Juli 2020

Pettersson A et al. Age at surgery for undescended testis and risk of testicular cancer. N Engl J Med. 2007;356(18):1835-41

Hemminki K, Li X. Familial risk in testicular cancer as a clue to a heritable and environmental aetiology. Br J Cancer. 2004;90(9):1765-70

von der Maase H et al. Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br Med J. 1986;293(6559):1398-1401

Adra N, Einhorn L. Testicular cancer update. Clin Adv Hematol Oncol. 2017;16(5):386-96

Dieckmann KP et al. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. J Clin Oncol. 2019;37(16):1412-23

The International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15:594-603

Mortensen MS et al. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol. 2014;66:1172-8

Tandstad T et al. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol. 2016;27(7):1299-304

10.

Mortensen MS et al. Surveillance versus adjuvant radiotherapy for patients with high risk stage I seminoma. Cancer. 2017;123:1212-8

11.

Honecker F et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol. 2018;29:1658-86

12.

Oldenburg J et al. Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. Ann Oncol. 2015;26:833-8

13.

Beyer J et al. Maintaining Success, Reducing Treatment Burden, Focussing on Survivorship: Highlights from the Third European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer. Ann Oncol. 2013;24:878-88

14.

Kollmannsberger C et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol. 2015;33:51-7

15.

Daugaard G et al. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. J Clin Oncol. 2014;32(34):3817-23

16.

Albers P et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol. 2008;26(18):2966-72

17.

Tandstad T et al. One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. Ann Oncol. 2014;25:2167-72

18.

Huddert RA et al. A single-arm trial evaluating one cycle of BEP as adjuvant chemotherapy in high-risk, stage 1 non-seminomatous or combined germ cell tumors of the testis (NSGCTT). J Clin Oncol. 2017;35(Suppl_15):1111

19.

Yu HY et al. Quality of surveillance for stage I testis cancer in the community. J Clin Oncol. 2009;27:4327-32

20.

Ernst DS et al. Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres. Can J Urol. 2005;12:2575-80

21.

Weissbach L et al. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol. 2000;37(5):582-94

22.

Saxman SB et al. Long-term follow-up of a phase III study of three versus four cyles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: The Indiana University experience. J Clin Oncol. 1998;16:702-6

23.

Toner GC et al. for the Australian and New Zealand Germ Cell Trial Group: Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Lancet. 2001;357:739-45

24.

Fankhauser CD et al. Improved survival in metastatic germ-cell cancer. Ann Oncol. 2018;29:347-51

25.

Hentrich M et al. Improved outcomes in metastatic germ cell cancer: results from a large cohort study. J Cancer Res Clin Oncol. 2020; https://doi.org/10.1007/s00432-020-03343-2

26.

de Wit R et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council J Clin Oncol. 2001;19(6):1629-40

27.

Culine S et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol. 2007;18(5):917-24

28.

De Wit R et al. Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin to standard BEP in intermediate prognosis germ cell-cancer. Intergroup Study EORTC 30983. J Clin Oncol. 2012;30:792-9

29.

Seidel C et al. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3). Urol Oncol. 2019;37(11):809.e19-809.e25

30.

Motzer RJ et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007;25:247-56

31.

Necchi A et al. High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. Ann Oncol. 2015;26(1):167-72

32.

Daugaard G et al. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974) Ann Oncol. 2011;22:1054-61

33.

Droz JP et al. Genito-Urinary Group of the French Federation of Cancer Centers (GETUG). Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol. 2007;51(3):739-46

34.

Feldman D et al. Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT). J Clin Oncol. 2018;36(15_Suppl):4508

35.

Fizazzi K et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol. 2014;15:1442-50

36.

Gillessen S et al. Redefining the IGCCCG classification in advanced non-seminoma. Ann Oncol. 2019;30(Suppl. 5):v357-358

37.

Beyer J et al. Prognostic factors in advanced seminoma: an analysis from the IGCCCG Update Consortium. J Clin Oncol. 38(6_Suppl):386

38.

Ravi P et al. A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor. Ann Oncol. 2014;25:331-8

39.

Fizazi K et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol. 2008;19:29-64

40.

Cathomas R et al. Questioning the value of fluorodeoxyglucose positron emission tomography for residual lesions after chemotherapy for metastatic seminoma: results of an International Global Germ Cell Cancer Group Registry. J Clin Oncol. 2018;36:3381-7

41.

Pico JL et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol. 2005;16:1152-9

42.

Adra N et al. Highdose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the Indiana University experience. J Clin Oncol. 2017;35(10):1096-102

43.

The International Prognostic Factors Study Group. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol. 2010;28:4906-11

44.

Lorch A et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol. 2011;29:2178-84

45.

Lorch A et al. Sequential versus single high-dose chemotherapy in relapsed or refractory germ cell tumors: Long-term results of a prospective randomized trial. J Clin Oncol. 2012;30:800-5

46.

Seidel C et al. Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group. Urol Oncol. 2016;34(4):167.e21-8

47.

Haugnes HS et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28(30):4649-57

Titel: Keimzelltumoren
Therapie von Hodentumoren
verfasst von: Priv.-Doz. Dr. med. Marcus Hentrich
Publikationsdatum: 16.11.2020
Verlag: Springer Medizin
Schlagwörter: Hodentumoren
Zytostatische Therapie
Hodentumoren
Seminom
Nichtseminom
Seminom
Nichtseminom
Erschienen in: InFo Hämatologie + Onkologie / Ausgabe 11/2020
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI: https://doi.org/10.1007/s15004-020-8271-5

Neu im Fachgebiet Onkologie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Springer Medizin

Therapie von Hodentumoren

Auszug

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2020

Revolution der Myelomtherapie?

Pembrolizumab in der Neoadjuvanz des frühen triple-negativen Mammakarzinoms

Passive Immunisierung mit Rekonvaleszentenplasma bei COVID-19?

Positive Ergebnisse für KRAS-Inhibitor

Aktuelle Erkenntnislage zum Verlauf einer SARS-CoV-2-Infektion

DLBCL: Welche zelluläre Immuntherapie soll es sein?

Neu im Fachgebiet Onkologie

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Update Onkologie